arry-520 and pomalidomide

arry-520 has been researched along with pomalidomide* in 2 studies

Trials

1 trial(s) available for arry-520 and pomalidomide

ArticleYear
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
    British journal of haematology, 2021, Volume: 192, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kinesins; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Orosomucoid; Spain; Thalidomide; Thiadiazoles; Treatment Outcome

2021

Other Studies

1 other study(ies) available for arry-520 and pomalidomide

ArticleYear
The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.
    Haematologica, 2017, Volume: 102, Issue:12

    Kinesin spindle protein inhibition is known to be an effective therapeutic approach in several malignancies. Filanesib (ARRY-520), an inhibitor of this protein, has demonstrated activity in heavily pre-treated multiple myeloma patients. The aim of the work herein was to investigate the activity of filanesib in combination with pomalidomide plus dexamethasone backbone, and the mechanisms underlying the potential synergistic effect. The ability of filanesib to enhance the activity of pomalidomide plus dexamethasone was studied in several

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Dexamethasone; Drug Synergism; Humans; Kinesins; Mice; Multiple Myeloma; Thalidomide; Thiadiazoles; Treatment Outcome

2017